A thorough evaluation of obesity as an effect modifier in clinical trials is warranted, and intentional weight loss may serve as adjunctive treatment in patients with obesity failing anti-TNF therapy. This evidence concerns the gene TNF and obesity due to melanocortin 4 receptor deficiency.